{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:20:59Z","timestamp":1782973259706,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jns.2022.120184","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T11:39:04Z","timestamp":1644838744000},"page":"120184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Neurological safety of subcutaneous tanezumab versus NSAID in patients with osteoarthritis"],"prefix":"10.1016","volume":"434","author":[{"given":"Mark T.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Sandroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip A.","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Gorson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn C.","family":"Pixton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fountaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Viktrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine R.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth M.","family":"Verburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jns.2022.120184_bb0005","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1097\/j.pain.0000000000001625","article-title":"Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety","volume":"160","author":"Schmelz","year":"2019","journal-title":"Pain."},{"issue":"1","key":"10.1016\/j.jns.2022.120184_bb0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/ALN.0b013e31821b1ac5","article-title":"Antagonism of nerve growth factor-TrkA signaling and the relief of pain","volume":"115","author":"Mantyh","year":"2011","journal-title":"Anesthesiology."},{"issue":"3","key":"10.1016\/j.jns.2022.120184_bb0015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/art.1780350315","article-title":"Nerve growth factor in the synovial fluid of patients with chronic arthritis","volume":"35","author":"Aloe","year":"1992","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.jns.2022.120184_bb0020","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/path.1108","article-title":"Nerve growth factor expression and innervation of the painful intervertebral disc","volume":"197","author":"Freemont","year":"2002","journal-title":"J. Pathol."},{"issue":"6","key":"10.1016\/j.jns.2022.120184_bb0025","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1023\/A:1022475432077","article-title":"Elevated nerve growth factor levels in the synovial fluid of patients with inflammatory joint disease","volume":"23","author":"Halliday","year":"1998","journal-title":"Neurochem. Res."},{"issue":"2","key":"10.1016\/j.jns.2022.120184_bb0030","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0306-4522(94)90366-2","article-title":"Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity","volume":"62","author":"Woolf","year":"1994","journal-title":"Neuroscience."},{"issue":"12","key":"10.1016\/j.jns.2022.120184_bb0035","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1464-5491.2009.02856.x","article-title":"Nerve growth factor and expression of its receptors in patients with diabetic neuropathy","volume":"26","author":"Kim","year":"2009","journal-title":"Diabet. Med."},{"issue":"1","key":"10.1016\/j.jns.2022.120184_bb0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4103\/joacp.JOACP_389_15","article-title":"Tanezumab: therapy targeting nerve growth factor in pain pathogenesis","volume":"34","author":"Patel","year":"2018","journal-title":"J. Anaesthesiol. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.jns.2022.120184_bb0045","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/pme.12677","article-title":"Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain","volume":"16","author":"Bramson","year":"2015","journal-title":"Pain Med."},{"issue":"16","key":"10.1016\/j.jns.2022.120184_bb0050","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa0901510","article-title":"Tanezumab for the treatment of pain from osteoarthritis of the knee","volume":"363","author":"Lane","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jns.2022.120184_bb0055","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/annrheumdis-2019-216296","article-title":"Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period","volume":"79","author":"Berenbaum","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jns.2022.120184_bb0060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2019.8044","article-title":"Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial","volume":"322","author":"Schnitzer","year":"2019","journal-title":"JAMA."},{"key":"10.1016\/j.jns.2022.120184_bb0065","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/JPR.S191297","article-title":"Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip","volume":"12","author":"Tive","year":"2019","journal-title":"J. Pain Res."},{"issue":"9","key":"10.1016\/j.jns.2022.120184_bb0070","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.pain.2013.04.035","article-title":"A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee","volume":"154","author":"Spierings","year":"2013","journal-title":"Pain."},{"issue":"11","key":"10.1016\/j.jns.2022.120184_bb0075","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3899\/jrheum.131294","article-title":"Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen","volume":"41","author":"Ekman","year":"2014","journal-title":"J. Rheumatol."},{"issue":"4819","key":"10.1016\/j.jns.2022.120184_bb0080","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1126\/science.3306916","article-title":"The nerve growth factor 35 years later","volume":"237","author":"Levi-Montalcini","year":"1987","journal-title":"Science."},{"issue":"6","key":"10.1016\/j.jns.2022.120184_bb0085","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/0092-8674(94)90378-6","article-title":"Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons","volume":"76","author":"Crowley","year":"1994","journal-title":"Cell."},{"issue":"6468","key":"10.1016\/j.jns.2022.120184_bb0090","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/368246a0","article-title":"Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk\/NGF receptor gene","volume":"368","author":"Smeyne","year":"1994","journal-title":"Nature."},{"issue":"6318","key":"10.1016\/j.jns.2022.120184_bb0095","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/350500a0","article-title":"Requirement for nerve growth factor in the development of myelinated nociceptors in vivo","volume":"350","author":"Ritter","year":"1991","journal-title":"Nature."},{"issue":"1\u20132","key":"10.1016\/j.jns.2022.120184_bb0100","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jns.2014.07.028","article-title":"Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment","volume":"345","author":"Brown","year":"2014","journal-title":"J. Neurol. Sci."},{"issue":"7","key":"10.1016\/j.jns.2022.120184_bb0105","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/art.41674","article-title":"Long-term safety and efficacy of subcutaneous Tanezumab versus nonsteroidal Antiinflammatory drugs for hip or knee osteoarthritis: a randomized trial","volume":"73","author":"Hochberg","year":"2021","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.jns.2022.120184_bb0110","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ana.410080608","article-title":"Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry","volume":"8","author":"Dyck","year":"1980","journal-title":"Ann. Neurol."},{"issue":"11","key":"10.1016\/j.jns.2022.120184_bb0115","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/art.41012","article-title":"The efficacy, tolerability, and joint safety of Fasinumab in osteoarthritis pain: a phase IIb\/III double-blind, placebo-controlled, randomized clinical trial","volume":"71","author":"Dakin","year":"2019","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jns.2022.120184_bb0120","article-title":"Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II\/III randomised clinical trial","author":"Dakin","year":"2020","journal-title":"Ann. Rheum. Dis."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22000466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22000466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:03:12Z","timestamp":1758384192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X22000466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":24,"alternative-id":["S0022510X22000466"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2022.120184","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurological safety of subcutaneous tanezumab versus NSAID in patients with osteoarthritis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2022.120184","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120184"}}